Locoregional Stomach Cancer
Gastric Adenocarcinoma
Female, 39 years
Patient Internal ID: 03598079
ICD-10 code
C16.2 Malignant Neoplasm of Body of Stomach
Diagnosis (Incl. Metastases/Stage) and Year
December 2019
Gastric Adenocarcinoma of Proximal Part ypT4aN2M0 LVI R0 G3 HER2(-). Disease progression in January 2021, Metastasis in the Ovaries.
Previous Treatment
Chemotherapy (FLOT scheme), Surgery (Gastrectomy), HIPEC (Cisplatin), Chemotherapy (FOLFOX scheme).
Prognosis and Survival Expectation
The prognosis remains poor, with a median survival of ~14 months from diagnosis for patients who received Gastric Resection and Postoperative Adjuvant Therapy.
Treatment Provided
Autologous DCV (7 doses) over a period of 6 months.
Patient Survival/Condition and Year
Date of Review: 02/12/2023
The patient has survived for 20 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy, Surgery and HIPEC, has extended patient survival by an estimate of around 6 months.
